Given the promising preclinical data and mounting evidence of the efficacy of PI3K/mTOR inhibitors in other cancer types, additional studies are needed to investigate PI3K/mTOR inhibitors in cSCC. This evidence concerns the gene MTOR and skin squamous cell carcinoma.